[Pharmacokinetic study of mycophenolic acid in pediatric kidney transplantation]

Area of Science:

• Pharmacology
• Nephrology
• Immunosuppression

Background:

• Mycophenolic acid (MPA) is crucial for immunosuppression in kidney transplantation (KT).
• MPA exhibits complex pharmacokinetics with significant variability.
• Monitoring trough concentration (C0) for MPA dosage adjustment is debated due to poor correlation with area under the curve (AUC).

Purpose of the Study:

• To establish the correlation between MPA trough concentration (C0) and area under the curve (AUC) in pediatric kidney transplant recipients.
• To determine optimal C0 ranges for achieving therapeutic AUC levels in this population.

Main Methods:

• Prospective study involving 54 pediatric kidney transplant patients on MPA.
• Linear regression and correlation analyses were used to assess the relationship between C0 and AUC.
• Group comparisons were made based on post-transplant duration and MPA formulation.

Main Results:

• C0 showed the best correlation with AUC (r² = 0.52).
• A significant proportion of patients (36.6%) had subtherapeutic MPA levels.
• An optimal C0 range of 1.42–4.55 µg/ml was identified for therapeutic AUC.
• Correlation improved after 3 months post-transplantation and with mycophenolate mofetil administration.

Conclusions:

• Trough concentration (C0) monitoring is recommended for MPA dose adjustment in pediatric KT patients, particularly beyond 3 months post-transplant.
• For early KT or complex cases, AUC monitoring is advised.
• Optimizing MPA dosing through C0 monitoring can improve immunosuppressive therapy effectiveness.